GLP1R and hydrops fetalis: The findings demonstrate consistent cardiovascular benefits of GLP-1 RAs, particularly semaglutide and exenatide, with notable reductions in major adverse cardiovascular events, cardiovascular mortality, and HF-related outcomes.